Sierra Oncology is exploring non-dilutive strategic options to support the continued development of its portfolio of DNA damage response (DDR) assets, including SRA737.
SRA737, which is a checkpoint kinase 1 (Chk1) inhibitor, was originally discove…
Sareum Holdings PLC (LON:SAR) has raised £681,000 which it will use to advance its TYK2/JAK1 inhibitor programme towards human trials.
The drug developer sold 170.37mln new shares at 0.4p as part of the fundraising, which was carried out on t…
@Sareumplc Latest tweet
Immuno-oncology (including Sareum's SDC-1802): All you wanted to know but were too afraid to ask… https://t.co/rM9L5tvHvs